INmune Bio (INMB) Stock Forecast, Price Target & Predictions
INMB Stock Forecast
INmune Bio stock forecast is as follows: an average price target of $22.00 (represents a 351.75% upside from INMB’s last price of $4.87) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
INMB Price Target
The average price target for INmune Bio (INMB) is $22.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $22.00 to $22.00. This represents a potential 351.75% upside from INMB's last price of $4.87.
INMB Analyst Ratings
According to 2 Wall Street analysts, INmune Bio's rating consensus is 'Buy'. The analyst rating breakdown for INMB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
INmune Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 22, 2024 | George Farmer | Scotiabank | - | - | 221.17% | 351.75% |
The latest INmune Bio stock forecast, released on Aug 22, 2024 by George Farmer from Scotiabank, set a price target of $22.00, which represents a 221.17% increase from the stock price at the time of the forecast ($6.85), and a 351.75% increase from INMB last price ($4.87).
INmune Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $22.00 |
| Last Closing Price | $4.87 | $4.87 | $4.87 |
| Upside/Downside | -100.00% | -100.00% | 351.75% |
In the current month, the average price target of INmune Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to INmune Bio's last price of $4.87. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 26, 2024 | Raymond James | Outperform | Initialise | |
| Sep 18, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Sep 18, 2024 | BTIG | Buy | Buy | Hold |
| Aug 21, 2024 | Scotiabank | Outperform | Initialise |
INmune Bio's last stock rating was published by Raymond James on Sep 26, 2024. The company Initialise its INMB rating from "null" to "Outperform".
INmune Bio Financial Forecast
INmune Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $-282.00K | $43.00K | $46.00K | $163.00K | $14.00K | $4.00K | - |
| Avg Forecast | - | - | - | - | $-3.33K | $333.00 | $14.00K | $28.00K | $43.00K | $46.00K | $38.00K | $226.67K | $1.45M | $3.26K | $83.50K |
| High Forecast | - | - | - | - | $-3.33K | $333.00 | $14.00K | $28.00K | $43.00K | $46.00K | $38.00K | $272.00K | $1.45M | $3.91K | $83.50K |
| Low Forecast | - | - | - | - | $-3.33K | $333.00 | $14.00K | $28.00K | $43.00K | $46.00K | $38.00K | $181.34K | $1.45M | $2.61K | $83.50K |
| # Analysts | - | - | - | - | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 17 | 8 | 10 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | -6.56% | 0.93% | 1.21% | 0.72% | 0.01% | 1.23% | - |
INmune Bio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $28.00K, with a low forecast of $28.00K, and a high forecast of $28.00K. INMB's average Quarter revenue forecast represents a -109.93% decrease compared to the company's last Quarter revenue of $-282.00K (Dec 23).
INmune Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 17 | 8 | 10 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | $45.07M | $-8.53M | $-6.41M | $-6.48M | $-9.46M | $-4.56M | $-1.90M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $-9.60M | $-1.20M | $-3.71M | $-1.81M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $-7.68M | $-1.20M | $-2.97M | $-1.45M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $-11.52M | $-1.20M | $-4.45M | $-2.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.67% | 7.88% | 1.23% | 1.05% |
1 analysts predict INMB's average Quarter EBITDA for Mar 24 to be -, with a high of - and a low of -. This is -100.00% lower than INmune Bio's previous annual EBITDA (Dec 23) of $45.07M.
INmune Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 17 | 8 | 10 | 8 |
| Net Income | - | - | - | - | - | - | - | - | $51.72M | $-8.56M | $-6.50M | $-7.33M | $-9.46M | $-4.56M | $-1.90M |
| Avg Forecast | $-8.38M | $-7.87M | $-8.28M | $-9.49M | $-11.28M | $-10.23M | $-12.72M | $-10.80M | $-8.61M | $-7.94M | $-8.00M | $-9.60M | $-7.00M | $-3.71M | $-1.80M |
| High Forecast | $-8.38M | $-7.87M | $-8.28M | $-9.49M | $-11.28M | $-10.23M | $-12.72M | $-10.80M | $-6.85M | $-7.94M | $-8.00M | $-7.68M | $-7.00M | $-2.97M | $-1.44M |
| Low Forecast | $-8.38M | $-7.87M | $-8.28M | $-9.49M | $-11.28M | $-10.23M | $-12.72M | $-10.80M | $-10.37M | $-7.94M | $-8.00M | $-11.52M | $-7.00M | $-4.45M | $-2.16M |
| Surprise % | - | - | - | - | - | - | - | - | -6.01% | 1.08% | 0.81% | 0.76% | 1.35% | 1.23% | 1.06% |
INmune Bio's average Quarter net income forecast for Mar 24 is $-10.80M, with a range of $-10.80M to $-10.80M. INMB's average Quarter net income forecast represents a -120.88% decrease compared to the company's last Quarter net income of $51.72M (Dec 23).
INmune Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 17 | 8 | 10 | 8 |
| SG&A | - | - | - | - | - | - | - | - | $2.40M | $2.59M | $2.31M | $2.33M | $2.52M | $2.06M | $1.81M |
| Avg Forecast | - | - | - | - | $-476.32K | $47.59K | $2.00M | $4.00M | $6.15M | $6.57M | $5.43M | $32.39M | $207.22M | $465.74K | $11.93M |
| High Forecast | - | - | - | - | $-476.32K | $47.59K | $2.00M | $4.00M | $6.15M | $6.57M | $5.43M | $38.87M | $207.22M | $558.64K | $11.93M |
| Low Forecast | - | - | - | - | $-476.32K | $47.59K | $2.00M | $4.00M | $6.15M | $6.57M | $5.43M | $25.91M | $207.22M | $372.57K | $11.93M |
| Surprise % | - | - | - | - | - | - | - | - | 0.39% | 0.39% | 0.43% | 0.07% | 0.01% | 4.43% | 0.15% |
INmune Bio's average Quarter SG&A projection for Mar 24 is $4.00M, based on 1 Wall Street analysts, with a range of $4.00M to $4.00M. The forecast indicates a 66.73% rise compared to INMB last annual SG&A of $2.40M (Dec 23).
INmune Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 17 | 8 | 10 | 8 |
| EPS | - | - | - | - | - | - | - | - | $1.21 | $-0.00 | $-0.00 | $-0.41 | $-0.55 | $-0.32 | $-0.20 |
| Avg Forecast | $-0.41 | $-0.39 | $-0.41 | $-0.47 | $-0.56 | $-0.51 | $-0.63 | $-0.54 | $-0.43 | $-0.39 | $-0.40 | $-0.57 | $-0.36 | $-0.27 | $-0.19 |
| High Forecast | $-0.41 | $-0.39 | $-0.41 | $-0.47 | $-0.56 | $-0.51 | $-0.63 | $-0.54 | $-0.34 | $-0.39 | $-0.40 | $-0.57 | $-0.36 | $-0.27 | $-0.19 |
| Low Forecast | $-0.41 | $-0.39 | $-0.41 | $-0.47 | $-0.56 | $-0.51 | $-0.63 | $-0.54 | $-0.51 | $-0.39 | $-0.40 | $-0.57 | $-0.36 | $-0.27 | $-0.19 |
| Surprise % | - | - | - | - | - | - | - | - | -2.84% | 0.00% | 0.00% | 0.72% | 1.52% | 1.17% | 1.05% |
According to 1 Wall Street analysts, INmune Bio's projected average Quarter EPS for Mar 24 is $-0.54, with a low estimate of $-0.54 and a high estimate of $-0.54. This represents a -144.21% decrease compared to INMB previous annual EPS of $1.21 (Dec 23).
INmune Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | - | - | 4275.00% | Buy |
| ANTX | AN2 Therapeutics | - | - | 552.99% | Buy |
| DRMA | Dermata Therapeutics | - | - | 426.32% | Buy |
| AVTE | Aerovate Therapeutics | - | - | 388.72% | Hold |
| INMB | INmune Bio | - | - | 351.75% | Buy |
| CUE | Cue Biopharma | - | - | 324.51% | Buy |
| ANEB | Anebulo Pharmaceuticals | - | - | 310.96% | Buy |
| TCRX | TScan Therapeutics | - | - | 181.69% | Buy |
| PYPD | PolyPid | - | - | 181.69% | Buy |
| ELYM | Eliem Therapeutics | - | - | 154.40% | Buy |
| ANIX | Anixa Biosciences | - | - | 134.38% | Buy |
| AVXL | Anavex Life Sciences | - | - | 20.75% | Buy |